Instem Announces Centrus Solution Suite for Early Drug Development
New Centrus™ Solution Suite to Provide Unique Capabilities for Accessing, Transforming, Viewing and Sharing Scientific Information in Early Drug Development
CONSHOHOCKEN, PA - (BUSINESS WIRE) – September 10, 2010 - - Instem, a leading provider of early drug development software solutions, announced today details of their newest product line, Centrus™, for enterprise information integration in early drug development. Centrus provides a single, secure environment to access, harmonize and use early drug development information from a variety of sources, including current data acquisition systems, legacy systems, warehouses, partner and contract research applications, to meet the rapidly-expanding needs of life science organizations for data-driven decision making.
Based on innovative Instem technology already licensed to clients to support electronic FDA submissions, the core of the Centrus suite is its open, service-oriented architecture with vendor-neutral communications and a data transformation strategy providing connectivity both inside and outside of an enterprise.
Offering an integrated global view of data from biology-related development activities ranging from lead optimization through phase I clinical, in areas such as the safety and efficacy assessment of drugs, diagnostics, biomarkers and medical devices, Centrus will prove to be highly efficient for both researchers and administrators. Rather than accessing multiple systems and relying on the capabilities they each may have, Centrus will provide sophisticated review, reporting and analytical capabilities across all systems and studies through a single access point.
“Centrus breaks the mold; it is truly unique in its pairing of advanced data aggregation technology with a variety of visualization capabilities that meet the unique needs of the nonclinical user,” commented Jennifer Feldmann, Instem’s Vice President of Business Development. “Only Instem has the depth of knowledge in early development data and workflows, the core technology, and the collaborative mindset to partner and integrate with other leading solution providers in the discovery, chemistry and clinical markets.”
During a period of strong growth opening new offices, expanding existing facilities and hiring more staff to support a growing number of users from new and existing clients, Instem is investing heavily in their Centrus solution suite. In addition to serving its existing market, Instem will continue to enter into new segments and geographies directly and through strategic partnerships with this newest offering.
“Centrus is the next logical step in the evolution of Instem’s 30 year commitment to the nonclinical research and development community,” stated Phil Reason, Instem CEO. “The continued globalization and restructuring of drug development activities demands a new approach to scientific knowledge management, and Centrus will finally allow organizations to unlock silos and leverage the information for better decision-making across the value chain. We see tremendous opportunity for our existing clients and for the development and regulatory communities as a whole.”
The Centrus solution suite will allow organizations to continue to use their chosen early development data acquisition systems, providing a single, powerful toolset to liberate the value in the data they have collected. Utilizing consistent, flexible and easy-to-use Centrus modules, day-to-day needs such as data review, comparative statistics and reporting can be met efficiently while supporting more specialized requirements such as the exchange of data between companies, electronic submissions and advanced analytics.
Connections with discovery and clinical data are also facilitated with Centrus, allowing early development information to integrate with translational science and comparative effectiveness research initiatives seeking to transfer research knowledge for improved patient outcomes.
Although a natural fit for users of Provantis®, Instem’s industry leading preclinical data management system, Centrus is designed to be completely data source independent and enables all organizations of any size involved in early drug development to take advantage of its benefits.
Instem is kicking off an international marketing campaign as they introduce Centrus to the early development market. In addition to on-site presentations, Instem will be holding numerous Web events and be working closely with strategic channel partners to demonstrate the power of their new solution suite.
More details about the Centrus suite and Instem’s promotional activities will be listed on a new section of their Web site, which will be unveiled later this month.
Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.
Meeting clients at the intersection of investment & return™.
Gary Mitchell (US HQ)
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600